Cardiovascular Autonomic Neuropathy
7
1
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
The Association Between Cognitive Function and Neuropathy in Individuals With Type 2 Diabetes
Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study
Clinical Validation of a Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System
Neurovascular Coupling and Autonomic Neuropathy in Type 2 Diabetes
Risk Analysis for Cardiovascular Autonomic Neuropathy
Genetic, Environment and Its Interaction Analysis for Cardiovascular Autonomic Neuropathy
The Relative Prevalence and Severity of Autonomic Nervous System Dysfunction